Search

Your search keyword '"Paterson, David L."' showing total 1,002 results
Start Over Author "Paterson, David L." Search Limiters Full Text
1,002 results on '"Paterson, David L."'

3. Statistical analysis plan for the BLING III study: A phase 3 multicentre randomised controlled trial of continuous versus intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis

Author

Billot, Laurent, Lipman, Jeffrey, Brett, Stephen J, de Waele, Jan J, Cotta, Menino Osbert, Davis, Joshua S, Finfer, Simon, Hammond, Naomi, Knowles, Serena, McGuinness, Shay, Myburgh, John, Paterson, David L, Peake, Sandra, Rajbhandari, Dorrilyn, Rhodes, Andrew, Roberts, Jason A, Roger, Claire, Shirwadkar, Charudatt, Starr, Therese, Taylor, Colman, and Dulhunty, Joel M

Published
2021

6. Integrative omics identifies conserved and pathogen-specific responses of sepsis-causing bacteria

Author

Mu, Andre, Klare, William P., Baines, Sarah L., Ignatius Pang, C. N., Guérillot, Romain, Harbison-Price, Nichaela, Keller, Nadia, Wilksch, Jonathan, Nhu, Nguyen Thi Khanh, Phan, Minh-Duy, Keller, Bernhard, Nijagal, Brunda, Tull, Dedreia, Dayalan, Saravanan, Chua, Hwa Huat Charlie, Skoneczny, Dominik, Koval, Jason, Hachani, Abderrahman, Shah, Anup D., Neha, Nitika, Jadhav, Snehal, Partridge, Sally R., Cork, Amanda J., Peters, Kate, Bertolla, Olivia, Brouwer, Stephan, Hancock, Steven J., Álvarez-Fraga, Laura, De Oliveira, David M. P., Forde, Brian, Dale, Ashleigh, Mujchariyakul, Warasinee, Walsh, Calum J., Monk, Ian, Fitzgerald, Anna, Lum, Mabel, Correa-Ospina, Carolina, Roy Chowdhury, Piklu, Parton, Robert G., De Voss, James, Beckett, James, Monty, Francois, McKinnon, Jessica, Song, Xiaomin, Stephen, John R., Everest, Marie, Bellgard, Matt I., Tinning, Matthew, Leeming, Michael, Hocking, Dianna, Jebeli, Leila, Wang, Nancy, Ben Zakour, Nouri, Yasar, Serhat A., Vecchiarelli, Stefano, Russell, Tonia, Zaw, Thiri, Chen, Tyrone, Teng, Don, Kassir, Zena, Lithgow, Trevor, Jenney, Adam, Cole, Jason N., Nizet, Victor, Sorrell, Tania C., Peleg, Anton Y., Paterson, David L., Beatson, Scott A., Wu, Jemma, Molloy, Mark P., Syme, Anna E., Goode, Robert J. A., Hunter, Adam A., Bowland, Grahame, West, Nicholas P., Wilkins, Marc R., Djordjevic, Steven P., Davies, Mark R., Seemann, Torsten, Howden, Benjamin P., Pascovici, Dana, Tyagi, Sonika, Schittenhelm, Ralf B., De Souza, David P., McConville, Malcolm J., Iredell, Jonathan R., Cordwell, Stuart J., Strugnell, Richard A., Stinear, Timothy P., Schembri, Mark A., and Walker, Mark J.

Published
2023
Full Text
View/download PDF

7. Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study

Author

Wang, Minggui, Earley, Michelle, Chen, Liang, Hanson, Blake M, Yu, Yunsong, Liu, Zhengyin, Salcedo, Soraya, Cober, Eric, Li, Lanjuan, Kanj, Souha S, Gao, Hainv, Munita, Jose M, Ordoñez, Karen, Weston, Greg, Satlin, Michael J, Valderrama-Beltrán, Sandra L, Marimuthu, Kalisvar, Stryjewski, Martin E, Komarow, Lauren, Luterbach, Courtney, Marshall, Steve H, Rudin, Susan D, Manca, Claudia, Paterson, David L, Reyes, Jinnethe, Villegas, Maria V, Evans, Scott, Hill, Carol, Arias, Rebekka, Baum, Keri, Fries, Bettina C, Doi, Yohei, Patel, Robin, Kreiswirth, Barry N, Bonomo, Robert A, Chambers, Henry F, Fowler, Vance G, Arias, Cesar A, van Duin, David, Investigators, Multi-Drug Resistant Organism Network, Abbo, Lilian M, Anderson, Deverick J, Chew, Kean Lee, Cross, Heather R, De, Partha Pratim, Desai, Samit, Dhar, Sorabh, Di Castelnuovo, Valentina, Diaz, Lorena, Dinh, AN Q, Eilertson, Brandon, Evans, Beth, Garcia-Diaz, Julia, Garner, Omai B, Greenwood-Quaintance, Kerryl, Hanson, Blake, Herc, Erica, Jacob, Jesse T, Jiang, Jianping, Kalayjian, Robert C, Kaye, Keith S, Kim, Angela, Lauterbach, Courtney, Marshall, Steven H, McCarty, Todd, Munita, Jose, Ng, Oon Tek, Gutierrez, Jose Millan Oñate, Peleg, Anton, Salata, Robert A, Schmidt-Malan, Suzannah, and Smitasin, Nares

Subjects
Pneumonia & Influenza, Lung, Clinical Research, Pneumonia, Infectious Diseases, Infection, Good Health and Well Being, Anti-Bacterial Agents, Bacteremia, Carbapenem-Resistant Enterobacteriaceae, Carbapenems, Cohort Studies, Humans, Klebsiella Infections, Klebsiella pneumoniae, Prospective Studies, Respiratory Sounds, Multi-Drug Resistant Organism Network Investigators, Clinical Sciences, Medical Microbiology, Public Health and Health Services, Microbiology
Abstract

BackgroundCarbapenem-resistant Klebsiella pneumoniae (CRKP) is a global threat. We therefore analysed the bacterial characteristics of CRKP infections and the clinical outcomes of patients with CRKP infections across different countries.MethodsIn this prospective, multicentre, cohort study (CRACKLE-2), hospitalised patients with cultures positive for CRKP were recruited from 71 hospitals in Argentina, Australia, Chile, China, Colombia, Lebanon, Singapore, and the USA. The first culture positive for CRKP was included for each unique patient. Clinical data on post-hospitalisation death and readmission were collected from health records, and whole genome sequencing was done on all isolates. The primary outcome was a desirability of outcome ranking at 30 days after the index culture, and, along with bacterial characteristics and 30-day all-cause mortality (a key secondary outcome), was compared between patients from China, South America, and the USA. The desirability of outcome ranking was adjusted for location before admission, Charlson comorbidity index, age at culture, Pitt bacteremia score, and anatomical culture source through inverse probability weighting; mortality was adjusted for the same confounders, plus region where relevant, through multivariable logistic regression. This study is registered at ClinicalTrials.gov, NCT03646227, and is complete.FindingsBetween June 13, 2017, and Nov 30, 2018, 991 patients were enrolled, of whom 502 (51%) met the criteria for CRKP infection and 489 (49%) had positive cultures that were considered colonisation. We observed little intra-country genetic variation in CRKP. Infected patients from the USA were more acutely ill than were patients from China or South America (median Pitt bacteremia score 3 [IQR 2-6] vs 2 [0-4] vs 2 [0-4]) and had more comorbidities (median Charlson comorbidity index 3 [IQR 2-5] vs 1 [0-3] vs 1 [0-2]). Adjusted desirability of outcome ranking outcomes were similar in infected patients from China (n=246), South America (n=109), and the USA (n=130); the estimates were 53% (95% CI 42-65) for China versus South America, 50% (41-61) for the USA versus China, and 53% (41-66) for the USA versus South America. In patients with CRKP infections, unadjusted 30-day mortality was lower in China (12%, 95% CI 8-16; 29 of 246) than in the USA (23%, 16-30; 30 of 130) and South America (28%, 20-37; 31 of 109). Adjusted 30-day all-cause mortality was higher in South America than in China (adjusted odds ratio [aOR] 4·82, 95% CI 2·22-10·50) and the USA (aOR 3·34, 1·50-7·47), with the mortality difference between the USA and China no longer being significant (aOR 1·44, 0·70-2·96).InterpretationGlobal CRKP epidemics have important regional differences in patients' baseline characteristics and clinical outcomes, and in bacterial characteristics. Research findings from one region might not be generalisable to other regions.FundingThe National Institutes of Health.

Published
2022

9. Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study

Author

van Duin, David, Arias, Cesar A, Komarow, Lauren, Chen, Liang, Hanson, Blake M, Weston, Gregory, Cober, Eric, Garner, Omai B, Jacob, Jesse T, Satlin, Michael J, Fries, Bettina C, Garcia-Diaz, Julia, Doi, Yohei, Dhar, Sorabh, Kaye, Keith S, Earley, Michelle, Hujer, Andrea M, Hujer, Kristine M, Domitrovic, T Nicholas, Shropshire, William C, Dinh, An, Manca, Claudia, Luterbach, Courtney L, Wang, Minggui, Paterson, David L, Banerjee, Ritu, Patel, Robin, Evans, Scott, Hill, Carol, Arias, Rebekka, Chambers, Henry F, Fowler, Vance G, Kreiswirth, Barry N, Bonomo, Robert A, and Investigators, Multi-Drug Resistant Organism Network

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Infectious Diseases, Clinical Research, Lung, Infection, Good Health and Well Being, Aged, Carbapenem-Resistant Enterobacteriaceae, Cohort Studies, Enterobacteriaceae Infections, Female, Humans, Male, Middle Aged, Phylogeny, Prospective Studies, United States, Multi-Drug Resistant Organism Network Investigators, Public Health and Health Services, Microbiology, Clinical sciences, Medical microbiology, Epidemiology
Abstract

BackgroundCarbapenem-resistant Enterobacterales (CRE) are a global threat. We aimed to describe the clinical and molecular characteristics of Centers for Disease Control and Prevention (CDC)-defined CRE in the USA.MethodsCRACKLE-2 is a prospective, multicentre, cohort study. Patients hospitalised in 49 US hospitals, with clinical cultures positive for CDC-defined CRE between April 30, 2016, and Aug 31, 2017, were included. There was no age exclusion. The primary outcome was desirability of outcome ranking (DOOR) at 30 days after index culture. Clinical data and bacteria were collected, and whole genome sequencing was done. This trial is registered with ClinicalTrials.gov, number NCT03646227.Findings1040 patients with unique isolates were included, 449 (43%) with infection and 591 (57%) with colonisation. The CDC-defined CRE admission rate was 57 per 100 000 admissions (95% CI 45-71). Three subsets of CDC-defined CRE were identified: carbapenemase-producing Enterobacterales (618 [59%] of 1040), non-carbapenemase-producing Enterobacterales (194 [19%]), and unconfirmed CRE (228 [22%]; initially reported as CRE, but susceptible to carbapenems in two central laboratories). Klebsiella pneumoniae carbapenemase-producing clonal group 258 K pneumoniae was the most common carbapenemase-producing Enterobacterales. In 449 patients with CDC-defined CRE infections, DOOR outcomes were not significantly different in patients with carbapenemase-producing Enterobacterales, non-carbapenemase-producing Enterobacterales, and unconfirmed CRE. At 30 days 107 (24%, 95% CI 20-28) of these patients had died.InterpretationAmong patients with CDC-defined CRE, similar outcomes were observed among three subgroups, including the novel unconfirmed CRE group. CDC-defined CRE represent diverse bacteria, whose spread might not respond to interventions directed to carbapenemase-producing Enterobacterales.FundingNational Institutes of Health.

Published
2020

10. Duration of Treatment for Pseudomonas aeruginosa Bacteremia: a Retrospective Study

Author

Babich, Tanya, Naucler, Pontus, Valik, John Karlsson, Giske, Christian G., Benito, Natividad, Cardona, Ruben, Rivera, Alba, Pulcini, Celine, Fattah, Manal Abdel, Haquin, Justine, Macgowan, Alasdair, Grier, Sally, Chazan, Bibiana, Yanovskay, Anna, Ami, Ronen Ben, Landes, Michal, Nesher, Lior, Zaidman-Shimshovitz, Adi, McCarthy, Kate, Paterson, David L., Tacconelli, Evelina, Buhl, Michael, Mauer, Susanna, Rodríguez-Baño, Jesús, de Cueto, Marina, Oliver, Antonio, de Gopegui, Enrique Ruiz, Cano, Angela, Machuca, Isabel, Gozalo-Marguello, Monica, Martinez-Martinez, Luis, Gonzalez-Barbera, Eva M., Alfaro, Iris Gomez, Salavert, Miguel, Beovic, Bojana, Saje, Andreja, Mueller–Premru, Manica, Pagani, Leonardo, Vitrat, Virginie, Kofteridis, Diamantis, Zacharioudaki, Maria, Maraki, Sofia, Weissman, Yulia, Paul, Mical, Dickstein, Yaakov, Leibovici, Leonard, and Yahav, Dafna

Published
2022
Full Text
View/download PDF

11. Shewanella spp. Bloodstream Infections in Queensland, Australia

Author

Laupland, Kevin B., Stewart, Adam G., Edwards, Felicity, Paterson, David L., Coulter, Sonali, Heney, Claire, George, Narelle, and Harris, Patrick

Subjects
Queensland -- Health aspects, Bacteremia -- Statistics -- Risk factors -- Demographic aspects, Shewanella -- Statistics -- Health aspects, Health
Abstract

Shewanella spp., most commonly S. algae and S. putrefaciens, are infrequent but occasionally severe causes of human infection associated with exposure to warm marine environments (2,2). Cases of otogenic and [...]

Published
2022
Full Text
View/download PDF

13. Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS).

Author

Evans, Scott R, Follmann, Dean, Liu, Ying, Holland, Thomas, Doernberg, Sarah B, Rouphael, Nadine, Hamasaki, Toshimitsu, Jiang, Yunyun, Lok, Judith J, Tran, Thuy Tien T, Harris, Anthony D, Fowler, Vance G, Boucher, Helen, Kreiswirth, Barry N, Bonomo, Robert A, Van Duin, David, Paterson, David L, and Chambers, Henry

Subjects
Clinical Trials and Supportive Activities, Patient Safety, Antimicrobial Resistance, Clinical Research, 6.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, 7.3 Management and decision making, Management of diseases and conditions, 5.1 Pharmaceuticals, Good Health and Well Being, Anti-Bacterial Agents, Clinical Decision-Making, Disease Management, Humans, Precision Medicine, Randomized Controlled Trials as Topic, Research Design, strategy, sequential randomization, pragmatic trial, Biological Sciences, Medical and Health Sciences, Microbiology
Abstract

Patient management is not based on a single decision. Rather, it is dynamic: based on a sequence of decisions, with therapeutic adjustments made over time. Adjustments are personalized: tailored to individual patients as new information becomes available. However, strategies allowing for such adjustments are infrequently studied. Traditional antibiotic trials are often nonpragmatic, comparing drugs for definitive therapy when drug susceptibilities are known. COMparing Personalized Antibiotic StrategieS (COMPASS) is a trial design that compares strategies consistent with clinical practice. Strategies are decision rules that guide empiric and definitive therapy decisions. Sequential, multiple-assignment, randomized (SMART) COMPASS allows evaluation when there are multiple, definitive therapy options. SMART COMPASS is pragmatic, mirroring clinical, antibiotic-treatment decision-making and addressing the most relevant issue for treating patients: identification of the patient-management strategy that optimizes the ultimate patient outcomes. SMART COMPASS is valuable in the setting of antibiotic resistance, when therapeutic adjustments may be necessary due to resistance.

Published
2019

18. Early oral stepdown antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial): study protocol for a multicentre, randomised controlled, open-label, phase III, non-inferiority trial

Author

Lee, I. Russel, Tong, Steven Y. C., Davis, Joshua S., Paterson, David L., Syed-Omar, Sharifah F., Peck, Kwong Ran, Chung, Doo Ryeon, Cooke, Graham S., Libau, Eshele Anak, Rahman, Siti-Nabilah B. A., Gandhi, Mihir P., Shi, Luming, Zheng, Shuwei, Chaung, Jenna, Tan, Seow Yen, Kalimuddin, Shirin, Archuleta, Sophia, and Lye, David C.

Published
2022
Full Text
View/download PDF

22. Comparison of nasopharyngeal swab vs. lower respiratory tract specimen PCR for the diagnosis of Pneumocystis jirovecii pneumonia

Author

Chew, Rusheng, primary, Tozer, Sarah, additional, Ulett, Kimberly, additional, Paterson, David L, additional, Whiley, David, additional, Sloots, Theo, additional, Fielding, David, additional, Zappala, Christopher, additional, Bashirzadeh, Farzad, additional, Hundloe, Justin, additional, Bletchley, Cheryl, additional, and Woods, Marion L, additional

Published
2024
Full Text
View/download PDF

24. Rapid nanopore sequencing and predictive susceptibility testing of positive blood cultures from intensive care patients with sepsis

Author

Harris, Patrick N. A., primary, Bauer, Michelle J., additional, Lüftinger, Lukas, additional, Beisken, Stephan, additional, Forde, Brian M., additional, Balch, Ross, additional, Cotta, Menino, additional, Schlapbach, Luregn, additional, Raman, Sainath, additional, Shekar, Kiran, additional, Kruger, Peter, additional, Lipman, Jeff, additional, Bialasiewicz, Seweryn, additional, Coin, Lachlan, additional, Roberts, Jason A., additional, Paterson, David L., additional, and Irwin, Adam D., additional

Published
2024
Full Text
View/download PDF

26. Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis

Author

Billot, Laurent, Lipman, Jeffrey, Brett, Stephen J., De Waele, Jan J., Cotta, Menino Osbert, Davis, Joshua S., Finfer, Simon, Hammond, Naomi E., Knowles, Serena, McGuinness, Shay, Myburgh, John, Paterson, David L., Peake, Sandra, Rajbhandari, Dorrilyn, Rhodes, Andrew, Roberts, Jason A., Roger, Claire, Shirwadkar, Charudatt, Starr, Therese, Taylor, Colman, and Dulhunty, Joel M.

Published
2021
Full Text
View/download PDF

27. Protocol for an international, multicentre, prospective, observational study of nosocomial pneumonia in intensive care units: The pneumoINSPIRE study

Author

Koulenti, Despoina, Armaganidis, Apostolos, Arvaniti, Kostoula, Blot, Stijn, Brun-Buisson, Christian, Deja, Maria, de Waele, Jan, Du, Bin, Dulhunty, Joel M, Garcia-Diaz, Julia, Judd, Matthew, Paterson, David L, Putensen, Christian, Reina, Rosa, Rello, Jordi, Restrepo, Marcos I, Roberts, Jason A, Sjovall, Fredrik, Timsit, Jean-Francois, Tsiodras, Sotirios, Zahar, Jean-Ralph, Zhang, Yuchi, and Lipman, Jeffrey

Published
2021

28. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?

Author

Marshall, Steven, Hujer, Andrea M, Rojas, Laura J, Papp-Wallace, Krisztina M, Humphries, Romney M, Spellberg, Brad, Hujer, Kristine M, Marshall, Emma K, Rudin, Susan D, Perez, Federico, Wilson, Brigid M, Wasserman, Ronald B, Chikowski, Linda, Paterson, David L, Vila, Alejandro J, van Duin, David, Kreiswirth, Barry N, Chambers, Henry F, Fowler, Vance G, Jacobs, Michael R, Pulse, Mark E, Weiss, William J, and Bonomo, Robert A

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Microbiology, Clinical Sciences, Medical Microbiology, Infectious Diseases, Antimicrobial Resistance, Vaccine Related, Emerging Infectious Diseases, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Infection, Animals, Anti-Bacterial Agents, Azabicyclo Compounds, Aztreonam, Ceftazidime, Colony Count, Microbial, Cyclophosphamide, Drug Administration Schedule, Drug Combinations, Drug Therapy, Combination, Enterobacteriaceae, Enterobacteriaceae Infections, Female, Gene Expression, Humans, Klebsiella Infections, Klebsiella pneumoniae, Mice, Microbial Sensitivity Tests, Neutropenia, Plasmids, Soft Tissue Infections, Thigh, beta-Lactam Resistance, beta-Lactamases, ceftazidime, avibactam, aztreonam, disk diffusion, metallo-beta-lactamases, metallo-β-lactamases, Pharmacology and Pharmaceutical Sciences, Medical microbiology, Pharmacology and pharmaceutical sciences
Abstract

Based upon knowledge of the hydrolytic profile of major β-lactamases found in Gram-negative bacteria, we tested the efficacy of the combination of ceftazidime-avibactam (CAZ-AVI) with aztreonam (ATM) against carbapenem-resistant enteric bacteria possessing metallo-β-lactamases (MBLs). Disk diffusion and agar-based antimicrobial susceptibility testing were initially performed to determine the in vitro efficacy of a unique combination of CAZ-AVI and ATM against 21 representative Enterobacteriaceae isolates with a complex molecular background that included blaIMP, blaNDM, blaOXA-48, blaCTX-M, blaAmpC, and combinations thereof. Time-kill assays were conducted, and the in vivo efficacy of this combination was assessed in a murine neutropenic thigh infection model. By disk diffusion assay, all 21 isolates were resistant to CAZ-AVI alone, and 19/21 were resistant to ATM. The in vitro activity of CAZ-AVI in combination with ATM against diverse Enterobacteriaceae possessing MBLs was demonstrated in 17/21 isolates, where the zone of inhibition was ≥21 mm. All isolates demonstrated a reduction in CAZ-AVI agar dilution MICs with the addition of ATM. At 2 h, time-kill assays demonstrated a ≥4-log10-CFU decrease for all groups that had CAZ-AVI with ATM (8 μg/ml) added, compared to the group treated with CAZ-AVI alone. In the murine neutropenic thigh infection model, an almost 4-log10-CFU reduction was noted at 24 h for CAZ-AVI (32 mg/kg every 8 h [q8h]) plus ATM (32 mg/kg q8h) versus CAZ-AVI (32 mg/kg q8h) alone. The data presented herein require us to carefully consider this new therapeutic combination to treat infections caused by MBL-producing Enterobacteriaceae.

Published
2017

33. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Author

Axfors, Cathrine, Janiaud, Perrine, Schmitt, Andreas M., van’t Hooft, Janneke, Smith, Emily R., Haber, Noah A., Abayomi, Akin, Abduljalil, Manal, Abdulrahman, Abdulkarim, Acosta-Ampudia, Yeny, Aguilar-Guisado, Manuela, Al-Beidh, Farah, Alejandria, Marissa M., Alfonso, Rachelle N., Ali, Mohammad, AlQahtani, Manaf, AlZamrooni, Alaa, Anaya, Juan-Manuel, Ang, Mark Angelo C., Aomar, Ismael F., Argumanis, Luis E., Averyanov, Alexander, Baklaushev, Vladimir P., Balionis, Olga, Benfield, Thomas, Berry, Scott, Birocco, Nadia, Bonifacio, Lynn B., Bowen, Asha C., Bown, Abbie, Cabello-Gutierrez, Carlos, Camacho, Bernardo, Camacho-Ortiz, Adrian, Campbell-Lee, Sally, Cao, Damon H., Cardesa, Ana, Carnate, Jose M., Castillo, German Jr. J., Cavallo, Rossana, Chowdhury, Fazle R., Chowdhury, Forhad U. H., Ciccone, Giovannino, Cingolani, Antonella, Climacosa, Fresthel Monica M., Compernolle, Veerle, Cortez, Carlo Francisco N., Costa Neto, Abel, D’Antico, Sergio, Daly, James, Danielle, Franca, Davis, Joshua S., De Rosa, Francesco Giuseppe, Denholm, Justin T., Denkinger, Claudia M., Desmecht, Daniel, Díaz-Coronado, Juan C., Díaz Ponce-Medrano, Juan A., Donneau, Anne-Françoise, Dumagay, Teresita E., Dunachie, Susanna, Dungog, Cecile C., Erinoso, Olufemi, Escasa, Ivy Mae S., Estcourt, Lise J., Evans, Amy, Evasan, Agnes L. M., Fareli, Christian J., Fernandez-Sanchez, Veronica, Galassi, Claudia, Gallo, Juan E., Garcia, Patricia J., Garcia, Patricia L., Garcia, Jesus A., Garigliany, Mutien, Garza-Gonzalez, Elvira, Gauiran, Deonne Thaddeus V., Gaviria García, Paula A., Giron-Gonzalez, Jose-Antonio, Gómez-Almaguer, David, Gordon, Anthony C., Gothot, André, Grass Guaqueta, Jeser Santiago, Green, Cameron, Grimaldi, David, Hammond, Naomi E., Harvala, Heli, Heralde, Francisco M., Herrick, Jesica, Higgins, Alisa M., Hills, Thomas E., Hines, Jennifer, Holm, Karin, Hoque, Ashraful, Hoste, Eric, Ignacio, Jose M., Ivanov, Alexander V., Janssen, Maike, Jennings, Jeffrey H., Jha, Vivekanand, King, Ruby Anne N., Kjeldsen-Kragh, Jens, Klenerman, Paul, Kotecha, Aditya, Krapp, Fiorella, Labanca, Luciana, Laing, Emma, Landin-Olsson, Mona, Laterre, Pierre-François, Lim, Lyn-Li, Lim, Jodor, Ljungquist, Oskar, Llaca-Díaz, Jorge M., López-Robles, Concepción, López-Cárdenas, Salvador, Lopez-Plaza, Ileana, Lucero, Josephine Anne C., Lundgren, Maria, Macías, Juan, Maganito, Sandy C., Malundo, Anna Flor G., Manrique, Rubén D., Manzini, Paola M., Marcos, Miguel, Marquez, Ignacio, Martínez-Marcos, Francisco Javier, Mata, Ana M., McArthur, Colin J., McQuilten, Zoe K., McVerry, Bryan J., Menon, David K., Meyfroidt, Geert, Mirasol, Ma. Angelina L., Misset, Benoît, Molton, James S., Mondragon, Alric V., Monsalve, Diana M., Moradi Choghakabodi, Parastoo, Morpeth, Susan C., Mouncey, Paul R., Moutschen, Michel, Müller-Tidow, Carsten, Murphy, Erin, Najdovski, Tome, Nichol, Alistair D., Nielsen, Henrik, Novak, Richard M., O’Sullivan, Matthew V. N., Olalla, Julian, Osibogun, Akin, Osikomaiya, Bodunrin, Oyonarte, Salvador, Pardo-Oviedo, Juan M., Patel, Mahesh C., Paterson, David L., Peña-Perez, Carlos A., Perez-Calatayud, Angel A., Pérez-Alba, Eduardo, Perkina, Anastasia, Perry, Naomi, Pouladzadeh, Mandana, Poyato, Inmaculada, Price, David J., Quero, Anne Kristine H., Rahman, Md. M., Rahman, Md. S., Ramesh, Mayur, Ramírez-Santana, Carolina, Rasmussen, Magnus, Rees, Megan A., Rego, Eduardo, Roberts, Jason A., Roberts, David J., Rodríguez, Yhojan, Rodríguez-Baño, Jesús, Rogers, Benjamin A., Rojas, Manuel, Romero, Alberto, Rowan, Kathryn M., Saccona, Fabio, Safdarian, Mehdi, Santos, Maria Clariza M., Sasadeusz, Joe, Scozzari, Gitana, Shankar-Hari, Manu, Sharma, Gorav, Snelling, Thomas, Soto, Alonso, Tagayuna, Pedrito Y., Tang, Amy, Tatem, Geneva, Teofili, Luciana, Tong, Steven Y. C., Turgeon, Alexis F., Veloso, Januario D., Venkatesh, Balasubramanian, Ventura-Enriquez, Yanet, Webb, Steve A., Wiese, Lothar, Wikén, Christian, Wood, Erica M., Yusubalieva, Gaukhar M., Zacharowski, Kai, Zarychanski, Ryan, Khanna, Nina, Moher, David, Goodman, Steven N., Ioannidis, John P. A., and Hemkens, Lars G.

Published
2021
Full Text
View/download PDF

36. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis: BLING III

Author

Lipman, Jeffrey, Brett, Stephen J., De Waele, Jan J., Cotta, Menino O., Davis, Joshua S., Finfer, Simon, Glass, Parisa, Knowles, Serena, McGuinness, Shay, Myburgh, John, Paterson, David L., Peake, Sandra, Rajbhandari, Dorrilyn, Rhodes, Andrew, Roberts, Jason A., Shirwadkar, Charudatt, Starr, Therese, Taylor, Colman, Billot, Laurent, and Dulhunty, Joel M.

Published
2019
Full Text
View/download PDF

37. A protocol for a phase 3 multicentre randomised controlled trial of continuous versus intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis: Bling III

Author

Lipman, Jeffrey, Brett, Stephen J, de Waele, Jan J, Cotta, Menino O, Davis, Joshua S, Finfer, Simon, Glass, Parisa, Knowles, Serena, McGuinness, Shay, Myburgh, John, Paterson, David L, Peake, Sandra, Rajbhandari, Dorrilyn, Rhodes, Andrew, Roberts, Jason A, Shirwadkar, Charudatt, Starr, Therese, Taylor, Colman, Billot, Laurent, and Dulhunty, Joel M

Published
2019

38. Comparing Polymerase Chain Reaction Testing of Nasopharyngeal Swab and Lower Respiratory Tract Specimens for the Diagnosis of Pneumocystis jirovecii Pneumonia.

Author

Chew, Rusheng, Tozer, Sarah, Ulett, Kimberly, Paterson, David L, Whiley, David, Sloots, Theo, Fielding, David, Zappala, Christopher, Bashirzadeh, Farzad, Hundloe, Justin, Bletchley, Cheryl, and Woods, Marion L

Abstract

Using nasopharyngeal (NP) swab samples instead of lower respiratory tract specimens for polymerase chain reaction (PCR) to diagnose Pneumocystis jirovecii pneumonia (PJP) may be better tolerated and improve diagnostic accessibility. In this 2-year Australian retrospective cohort study of patients with clinically suspected PJP, P jirovecii PCR on NP swab samples had perfect specificity but low sensitivity (0.66). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. In vitro, in vivo and clinical studies comparing the efficacy of ceftazidime-avibactam monotherapy with ceftazidime-avibactam-containing combination regimens against carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa isolates or infections: a scoping review

Author

Aslan, Abdullah Tarık, primary, Ezure, Yukiko, additional, Horcajada, Juan Pablo, additional, Harris, Patrick N. A., additional, and Paterson, David L., additional

Published
2023
Full Text
View/download PDF

40. ACORN (A Clinically-Oriented Antimicrobial Resistance Surveillance Network) II: protocol for case based antimicrobial resistance surveillance

Author

Mo, Yin, primary, Ding, Ying, additional, Cao, Yang, additional, Hopkins, Jill, additional, Ashley, Elizabeth A., additional, Waithira, Naomi, additional, Wannapinij, Prapass, additional, Lee, Sue J., additional, Ling, Claire L., additional, Hamers, Raph L., additional, Roberts, Tamalee, additional, Lubell, Yoel, additional, Karkey, Abhilasha, additional, Akech, Samuel, additional, Lissauer, Samantha, additional, Opintan, Japheth, additional, Okeke, Iruka, additional, Eremin, Sergey, additional, Tornimbene, Barbara, additional, Hsu, Li Yang, additional, Thwaites, Louise, additional, Lam, Minh Yen, additional, Pham, Ngoc Thach, additional, Pham, Tieu Kieu, additional, Teo, Jeanette, additional, Kwa, Andrea Lay-Hoon, additional, Marimuthu, Kalisvar, additional, Ng, Oon Tek, additional, Vasoo, Shawn, additional, Kitsaran, Suwatthiya, additional, Anunnatsiri, Siriluck, additional, Kosalaraksa, Pope, additional, Chotiprasitsakul, Darunee, additional, Santanirand, Pitak, additional, Plongla, Rongpong, additional, Chua, Hock Hin, additional, Tiong, Xun Ting, additional, Wong, Ke Juin, additional, Ponnampalavanar, Sasheela Sri La Sri, additional, Sulaiman, Helmi Bin, additional, Mazlan, Mohd Zulfakar, additional, Salmuna, Zeti Norfidiyati, additional, Rajahram, Giri Shan, additional, Zaili, Mohd Zaki Bin Mohd, additional, Francis, Joshua R., additional, Sarmento, Nevio, additional, Guterres, Helio, additional, Oakley, Tessa, additional, Yan, Jennifer, additional, Tilman, Ari, additional, Khalid, Muhammad Osama Rehman, additional, Hashmi, Madiha, additional, Mahmood, Syed Faisal, additional, Dhiloo, Azizullah Khan, additional, Fatima, Ambreen, additional, Lubis, Inke Nadia D., additional, Wijaya, Hendri, additional, Abad, Cybele L., additional, Roman, Arthur Dessi, additional, Lazarte, Cecilia C. Maramba, additional, Mamun, Gazi Md. Salahuddin, additional, Asli, Rosmonaliza, additional, Momin, Muhd Haziq Fikry bin Haji Abdul, additional, Nyamdavaa, Khurelbaatar, additional, Gurjav, Ulziijargal, additional, Bory, Sotharith, additional, Varghese, George M., additional, Gupta, Lalit, additional, Tantia, Pratik, additional, Sinto, Robert, additional, Doi, Yohei, additional, Khanal, Basudha, additional, Malijan, Greco, additional, Lazaro, Jezreel, additional, Gunasekara, Samanmalee, additional, Withanage, Sumudu, additional, Liu, Po Yu, additional, Xiao, Yonghong, additional, Wang, Minggui, additional, Paterson, David L., additional, Doorn, H. Rogier van, additional, and Turner, Paul, additional

Published
2023
Full Text
View/download PDF

42. Clostridioides difficileInfection: Clinical Practice and Health Outcomes in 6 Large Tertiary Hospitals in Eastern Australia

Author

Stewart, Adam G, primary, Chen, Sharon C A, additional, Hamilton, Kate, additional, Harris-Brown, Tiffany, additional, Korman, Tony M, additional, Figtree, Melanie, additional, Worth, Leon J, additional, Kok, Jen, additional, Van der Poorten, David, additional, Byth, Karen, additional, Slavin, Monica A, additional, and Paterson, David L, additional

Published
2023
Full Text
View/download PDF

43. Integrating multiple genomic technologies to investigate an outbreak of carbapenemase-producing Enterobacter hormaechei

Author

Roberts, Leah W., Harris, Patrick N. A., Forde, Brian M., Ben Zakour, Nouri L., Catchpoole, Elizabeth, Stanton-Cook, Mitchell, Phan, Minh-Duy, Sidjabat, Hanna E., Bergh, Haakon, Heney, Claire, Gawthorne, Jayde A., Lipman, Jeffrey, Allworth, Anthony, Chan, Kok-Gan, Chong, Teik Min, Yin, Wai-Fong, Schembri, Mark A., Paterson, David L., and Beatson, Scott A.

Published
2020
Full Text
View/download PDF

44. Gram-negative neonatal sepsis in low- and lower-middle-income countries and WHO empirical antibiotic recommendations: A systematic review and meta-analysis

Author

Wen, Sophie C. H., Ezure, Yukiko, Rolley, Lauren, Spurling, Geoff, Lau, Colleen L., Riaz, Saba, Paterson, David L., and Irwin, Adam D.

Subjects
Infants (Newborn) -- Diseases, Practice guidelines (Medicine) -- International aspects, Developing countries -- Health aspects, Gram-negative bacterial infections -- Risk factors -- Demographic aspects -- Statistics -- Drug therapy, Sepsis -- Risk factors -- Demographic aspects -- Statistics -- Drug therapy, Pediatric research, Biological sciences, World Health Organization -- Standards
Abstract

Background Neonatal sepsis is a significant global health issue associated with marked regional disparities in mortality. Antimicrobial resistance (AMR) is a growing concern in Gram-negative organisms, which increasingly predominate in neonatal sepsis, and existing WHO empirical antibiotic recommendations may no longer be appropriate. Previous systematic reviews have been limited to specific low- and middle-income countries. We therefore completed a systematic review and meta-analysis of available data from all low- and lower-middle-income countries (LLMICs) since 2010, with a focus on regional differences in Gram-negative infections and AMR. Methods and findings All studies published from 1 January 2010 to 21 April 2021 about microbiologically confirmed bloodstream infections or meningitis in neonates and AMR in LLMICs were assessed for eligibility. Small case series, studies with a small number of Gram-negative isolates ( Conclusions Gram-negative bacteria are an important cause of neonatal sepsis in LLMICs and are associated with significant rates of resistance to WHO-recommended first- and second-line empirical antibiotics. AMR surveillance should underpin region-specific empirical treatment recommendations. Meanwhile, a significant global commitment to accessible and effective antimicrobials for neonates is required., Author(s): Sophie C. H. Wen 1,2,*, Yukiko Ezure 1,3, Lauren Rolley 2, Geoff Spurling 4, Colleen L. Lau 3,5, Saba Riaz 6, David L. Paterson 1,7, Adam D. Irwin 1,2 [...]

Published
2021
Full Text
View/download PDF

46. Corrigendum to “Statistical analysis plan for the BLING III study: a phase 3 multicentre randomised controlled trial of continuous versus intermittent β-lactam antibiotic infusion in critically ill patients with sepsis” [Crit Care Resusc 23(3) (2021) 273–284]

Author

Billot, Laurent, primary, Lipman, Jeffrey, additional, Brett, Stephen J., additional, De Waele, Jan J., additional, Cotta, Menino Osbert, additional, Davis, Joshua S., additional, Finfer, Simon, additional, Hammond, Naomi, additional, Knowles, Serena, additional, McGuinness, Shay, additional, Myburgh, John, additional, Paterson, David L., additional, Peake, Sandra, additional, Rajbhandari, Dorrilyn, additional, Rhodes, Andrew, additional, Roberts, Jason A., additional, Roger, Claire, additional, Shirwadkar, Charudatt, additional, Starr, Therese, additional, Taylor, Colman, additional, and Dulhunty, Joel M., additional

Published
2023
Full Text
View/download PDF

47. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study

Author

Reyes, Jinnethe, primary, Komarow, Lauren, additional, Chen, Liang, additional, Ge, Lizhao, additional, Hanson, Blake M, additional, Cober, Eric, additional, Herc, Erica, additional, Alenazi, Thamer, additional, Kaye, Keith S, additional, Garcia-Diaz, Julia, additional, Li, Lanjuan, additional, Kanj, Souha S, additional, Liu, Zhengyin, additional, Oñate, Jose M, additional, Salata, Robert A, additional, Marimuthu, Kalisvar, additional, Gao, Hainv, additional, Zong, Zhiyong, additional, Valderrama-Beltrán, Sandra L, additional, Yu, Yunsong, additional, Tambyah, Paul, additional, Weston, Gregory, additional, Salcedo, Soraya, additional, Abbo, Lillian M, additional, Xie, Qing, additional, Ordoñez, Karen, additional, Wang, Minggui, additional, Stryjewski, Martin E, additional, Munita, Jose M, additional, Paterson, David L, additional, Evans, Scott, additional, Hill, Carol, additional, Baum, Keri, additional, Bonomo, Robert A, additional, Kreiswirth, Barry N, additional, Villegas, Maria Virginia, additional, Patel, Robin, additional, Arias, Cesar A, additional, Chambers, Henry F, additional, Fowler, Vance G, additional, Doi, Yohei, additional, van Duin, David, additional, Satlin, Michael J, additional, Reyes, Jinnethe, additional, Hanson, Blake, additional, Kaye, Keith, additional, Kanj, Souha, additional, Oñate, Jose, additional, Salata, Robert, additional, Valderrama-Beltrán, Sandra, additional, Abbo, Lillian, additional, Stryjewski, Martin, additional, Munita, Jose, additional, Paterson, David, additional, Bonomo, Robert, additional, Kreiswirth, Barry, additional, Virginia Villegas, Maria, additional, Arias, Cesar, additional, Chambers, Henry, additional, Fowler, Vance, additional, and Satlin, Michael, additional

Published
2023
Full Text
View/download PDF

50. Higher rates of cefiderocol resistance among NDM producing Klebsiella bloodstream isolates applying EUCAST over CLSI breakpoints

Author

Isler, Burcu, Vatansever, Cansel, Özer, Berna, Çınar, Güle, Aslan, Abdullah Tarık, Falconer, Caitlin, Bauer, Michelle J., Forde, Brian, Şimşek, Funda, Tülek, Necla, Demirkaya, Hamiyet, Menekşe, Şirin, Akalin, Halis, Balkan, İlker İnanç, Aydın, Mehtap, Tigen, Elif Tükenmez, Demir, Safiye Koçulu, Kapmaz, Mahir, Keske, Şiran, Doğan, Özlem, Arabacı, Çiğdem, Yağcı, Serap, Hazırolan, Gülşen, Bakır, Veli Oğuzalp, Gönen, Mehmet, Saltoğlu, Neşe, Azap, Alpay, Azap, Özlem, Akova, Murat, Ergönül, Önder, Can, Füsun, Paterson, David L., and Harris, Patrick N. A.

Abstract

Cefiderocol is generally active against carbapenem-resistant Klebsiella spp. (CRK) with higher MICs against metallo-beta-lactamase producers. There is a variation in cefiderocol interpretive criteria determined by EUCAST and CLSI. Our objective was to test CRK isolates against cefiderocol and compare cefiderocol susceptibilities using EUCAST and CLSI interpretive criteria. A unique collection (n = 254) of mainly OXA-48-like- or NDM-producing CRK bloodstream isolates were tested against cefiderocol with disc diffusion (Mast Diagnostics, UK). Beta-lactam resistance genes and multilocus sequence types were identified using bioinformatics analyses on complete bacterial genomes. Median cefiderocol inhibition zone diameter was 24 mm (interquartile range [IQR] 24–26 mm) for all isolates and 18 mm (IQR 15–21 mm) for NDM producers. We observed significant variability between cefiderocol susceptibilities using EUCAST and CLSI breakpoints, such that 26% and 2% of all isolates, and 81% and 12% of the NDM producers were resistant to cefiderocol using EUCAST and CLSI interpretive criteria, respectively. Cefiderocol resistance rates among NDM producers are high using EUCAST criteria. Breakpoint variability may have significant implications on patient outcomes. Until more clinical outcome data are available, we suggest using EUCAST interpretive criteria for cefiderocol susceptibility testing.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results